CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
28 hedge funds and large institutions have $2.55M invested in CASI Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
4% more capital invested
Capital invested by funds: $2.45M → $2.55M (+$103K)
0.37% more ownership
Funds ownership: 0% → 0.37% (+0.37%)
3% less funds holding
Funds holding: 29 → 28 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$86.9K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$45K |
| 3 |
PIM
Penobscot Investment Management
Boston,
Massachusetts
|
+$37K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
-$39.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$28K |
| 3 |
Goldman Sachs
New York
|
-$27K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 5 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$17K |
CASI Hedge Fund Activity: Q4 2016 in Review
28 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2016, worth a combined $2.55M — up 4.2% from $2.45M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CASI and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $86.9K. The largest seller was Wellington Shields Capital Management, cutting an estimated $39.5K.
- 28 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2016, down from 29 in Q3 2016.
- Funds reported $2.55M of CASI Pharmaceuticals stock for Q4 2016, up 4.2% quarter-over-quarter.
- 2 funds opened new CASI Pharmaceuticals positions in Q4 2016 and 3 closed out, a net change of -1 holder.
- The largest CASI Pharmaceuticals buyer in Q4 2016 was Renaissance Technologies, an estimated $86.9K added.
- The largest CASI Pharmaceuticals seller in Q4 2016 was Wellington Shields Capital Management, an estimated $39.5K sold.
Based on aggregated 13F filings for Q4 2016.